2022 Annual Meeting | C169 - Myelopathies: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes

Date Thursday 04/07/22

Time 03:30 PM - 05:30 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Benjamin M. Greenberg, MD, FAAN

Topic(s) General Neurology

Learning Objectives Participants should be familiar with the differential diagnosis of acute and subacute myelopathy; the testing and management of patients with suspected myelitis; and recognize the red flags for vascular myelopathies and understand the indications for obtaining spinal angiograms.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
03:30 PM - 04:15 PM PDT	Speaker	Introduction to Myelopathies and Myelitis Benjamin M. Greenberg, MD, FAAN
03:30 PM - 03:30 PM PDT	Speaker	Walk-in Slides Benjamin M. Greenberg, MD, FAAN
04:15 PM - 05:00 PM PDT	Speaker	Vascular Myelopathies Philippe Gailloud, MD
05:00 PM - 05:30 PM PDT	Speaker	Case Challenges Benjamin M. Greenberg, MD, FAAN, Philippe Gailloud, MD

Faculty Disclosures
Benjamin M. Greenberg, MD, FAAN	Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/ROche. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Clene. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Greenberg has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Siegel Rare Neuroimmune Association. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Carlton Fields. Dr. Greenberg has stock in GenrAb. Dr. Greenberg has stock in Clene. The institution of Dr. Greenberg has received research support from Anokion. The institution of Dr. Greenberg has received research support from Regeneron. Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care. Dr. Greenberg has received publishing royalties from a publication relating to health care.
Philippe Gailloud, MD	Dr. Gailloud has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cerenovus. Dr. Gailloud has received stock or an ownership interest from ArtVentive. The institution of Dr. Gailloud has received research support from Siemens Medical.